Threonine
Research stageAlso known as (2S)-threonine, (2S,3R)-(-)-Threonine, 2-Amino-3-hydroxybutyric acid, Aminosyn 10%, Sulfite-Free+45 more
(2S)-threonine, (2S,3R)-(-)-Threonine, 2-Amino-3-hydroxybutyric acid, Aminosyn 10%, Sulfite-Free, Aminosyn 3.5 % M, Sulfite Free, Aminosyn 8.5 % with Electrolytes, Sulfite-Free, Aminosyn 8.5%, Sulfite-Free, Aminosyn II 10 %, Aminosyn II 15%, Aminosyn II 8.5 % with Electrolytes, Sulfite-Free, Aminosyn II 8.5 %, Sulfite-Free, Aminosyn-HBC 7 %, Sulfite-Free, Aminosyn-PF 10 %, Sulfite-Free, Aminosyn-PF 7%, Clinisol 15, Freamine III 10, Hepatamine 8, Hepatasol, L-(-)-Threonine, L-2-Amino-3-hydroxybutyric acid, L-Threonin, L-Threonine, L-alpha-amino-beta-hydroxybutyric acid, Nephramine, Plenamine, PremaSol, ProSol, ProcalAmine 3, Thr, Threostat, Travasol 10, Travasol 10%, Treonina, Trophamine, Trophamine 10 %, Trophamine 6 %, Clinimix 4.25/10, Clinimix 4.25/25, Clinimix 4.25/5, Clinimix 5/15, Clinimix 5/20, Clinimix 5/25, Clinimix E 2.75/5, Clinimix E 4.25/10, Clinimix E 4.25/5, Clinimix E 5/15, Clinimix E 5/20, Clinimix E 5/25, Threoninum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Journals, researchers & institutions
- Annals of neurology1
- Aisen PS1
- Blennow K1
- Clark CM1
- Dean R1
- Knapik-Czajka M1
- Lee VM1
- Lewczuk P1
- Petersen RC1
- Department of Pathology and Laboratory Medicine1
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature